BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 9, 2026
Home » Blogs » BioWorld MedTech Perspectives » FDA, devices and doom and gloom

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Diagnostics / CDRH / FDA

FDA, devices and doom and gloom

May 25, 2011
By Mark McCarty

Is the sky falling? Device makers keep saying so

By MARK McCARTY

Medical Device Daily Washington Editor

FDA's Center for Devices and Radiological Health is certainly on a regulatory tear of late, and industry is understandably rattled by some of the developments. After all, CDRH only recently managed to shed a couple of obvious malcontents in the persons of Robert Smith, MD, and Julian Nichols, MD, who both worked at the Office of Device Evaluation at CDRH and were not exactly happy to get their walking papers. My impression is that you have to be either really obnoxious, noticeably incompetent, or both to lose a job with Uncle Sam, so it's difficult to avoid the conclusion that these two had some serious baggage and went out of their way to make trouble.

Even without the aforementioned renegades, industry has a lot of gripes about how things are done at CDRH, which is notoriously underfunded and unable to keep pace with everything that lands in its lap. Still, industry has a bad habit of declaring small device makers an endangered species. This didn't seem entirely speculative in early 2009, when the economy tottered on the verge of collapse. Back then, changes were on the horizon at FDA, venture capital looked nervous, and the U.S. Patent and Trademark Office was bogged down with roughly three quarters of a million patent applications with an average pendency of 36 months.

Things have stabilized since then, but the doomsday talk hasn't abated. For instance, I recently interviewed the principal of a small device firm who said industry was carefully watching the fate of his company's application and that a failure by FDA to approve the application would have “dire” consequences for the entire industry.

To some extent, a reworking of the approval and clearance processes at CDRH was needed, although some of the proposals put forth by the agency seem a bit off the charts. All the same, this business of saying in more or less veiled terms that the sky is falling is just absurd. When you look at per-capita income in the U.S. and the sheer amounts spent on healthcare here, the concept that device makers will utterly abandon the U.S. is just silly. And claiming industry will bail out is dishonest, because we all know better.

Just for the record, I don't go to church – not routinely anyway – and haven't since the age of 15, so I can't say for certain I'd know the Crack of Doom if I heard it. All the same, I'm not deaf, and I know that even in the face of Euro-flight, device makers will still want and need the U.S. market for at least as long as any of us are alive. After all, who can say no to a market measured in the trillions of dollars?

So please industry, no more apocalyptic forecasts. It's getting old. Not interesting, just old.

Is this really necessary?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 6, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing